<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43358">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656525</url>
  </required_header>
  <id_info>
    <org_study_id>JP22431</org_study_id>
    <secondary_id>JapicCTI-121849</secondary_id>
    <nct_id>NCT01656525</nct_id>
  </id_info>
  <brief_title>A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients</brief_title>
  <official_title>A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <authority>Ministry of Health, Labor and Welfare Board Affiliation:JAPAN</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and
      preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild
      to moderate AD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Gantenerumab in plasma</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF/plasma ratios of Gantenerumab.</measure>
    <time_frame>Baseline, Day183</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma  Abeta</measure>
    <time_frame>Baseline,Day183</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma and CSF tau</measure>
    <time_frame>Baseline,Day183</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mini-Mental State Examination (MMSE) and Alzheimer's disease assessment scale cognitive behaviors (ADAS-Cog).</measure>
    <time_frame>Baseline,Day85, 197, 253</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>75 mg subcutaneous doses every 4 weeks for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>105 mg subcutaneous doses every 4 weeks for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>225 mg subcutaneous doses every 4 weeks for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous doses every 4 weeks for 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria

          -  Meet DSM-IV criteria for Dementia of the Alzheimer type

          -  MMSE score : 16 to 26 etc.

        Exclusion Criteria:

          -  Meet the exclusion criteria of MRI at screening.

          -  A history of significant neurodegenerative diseases or dementia  other than
             Alzheimer's disease.

        etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akira Chiba</last_name>
    <email>clinical-trials@chugai-pharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kansai region</name>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Chiba</last_name>
      <email>clinical-trials@chugai-pharm.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanto region,</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Chiba</last_name>
      <email>clinical-trials@chugai-pharm.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu region</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Chiba</last_name>
      <email>clinical-trials@chugai-pharm.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokai region</name>
      <address>
        <city>Toakai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Chiba</last_name>
      <email>clinical-trials@chugai-pharm.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku region</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Chiba</last_name>
      <email>clinical-trials@chugai-pharm.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>June 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
